Consecutive lynestrenol and cross-sex hormone treatment in biological female adolescents with gender dysphoria: a retrospective analysis Prior to the start of cross-sex hormone therapy (CSH), androgenic progestins are often used to induce amenorrhea in female to male (FtM) pubertal adolescents with gender dysphoria (GD). The aim of this single-center study is to report changes in anthropometry , side effects, safety parameters, and hormone levels in a relatively large cohort of FtM adolescents with a diagnosis of GD at Tanner stage B4 or further, who were treated with lynestrenol (Orgametril®) monotherapy and in combination with testosterone esters (Sustanon®). A retrospective analysis of clinical and biochemical data obtained during at least 6 months of hormonal treatment in FtM adolescents
Comparison of the efficacy of micronized progesterone and lynestrenol in treatment of simple endometrial hyperplasia without atypia. To evaluate the treatment of simple endometrial hyperplasia without atypia with different gestagens. Sixty premenopausal women with histologically documented endometrial hyperplasia without atypia were included in this prospective controlled study. Patients were randomized into two groups: Group I included 30 patients who received lynestrenol (LYN) in a dose of 15 mg/d, while Group II included 30 patients who received micronized progesterone (MP) 200 mg/d for 12 days per cycle for 3 months. Patients were reevaluated with endometrial curettage after treatment. MP and LYN regimens were compared to regression, resolution or persistence rates and metabolic parameters
haemoglobin HbA1c haemoglobin A1c Hct haematocrit HDL high-density lipoprotein 2 Evidence for effective interventions for children and young people with gender dysphoria | Sax Institute K+ potassium L lynestrenol LDL low-density lipoprotein LH luteinising hormone LS lumbar spine MPA medroxyprogesterone acetate NOS not otherwise specified RCHGS Royal Children’s Hospital Gender Service OC oral
progesterone and lynestrenol in treatment of simple endometrial hyperplasia without atypia. Arch Gynecol Obstet 2014; 290: 83– 6. doi: 10.1007/s00404-014-3161-4Article Locations:Article LocationTehranian A, Ghahghaei-Nezamabadi A, Arab M, Khalagi K, Aghajani R, Sadeghi S. The impact of adjunctive metformin to progesterone for the treatment of non-atypical endometrial hyperplasia in a randomized fashion
; progestogen implants, 0.31 (0.26-0.37) per 1,000 woman-years; oral medium-dose progestogen (desogestrel 75 mg), 0.24 per 1,000 woman-years, (0.21-0.27); and oral low-dose progestogen (norethisterone 0.35 mg and lynestrenol 0.5 mg), 0.81 (0.70-0.93) per 1,000 woman-years. Hormonal contraception lowers the risk of ectopic pregnancy markedly. The incidence rate of ectopic pregnancy among women using a low-dose
-center, randomized study in breastfeeding women compared a copper-containing IUD (Multiload Cu250) with an oral progestin-only contraceptive (lynestrenol 500 mcg). There were no statistically significant differences between groups with regard to infant anthropometric parameters and child health, except a lower incidence of child illness after 6 months in the lynestrenol group.[6]Three hundred twenty contraceptive (lynestrenol 500 mcg; n = 117), and levonorgestrel implants (Norplant; n = 120) in lactating women. After the first year of use, none of the methods affected the rate of infant growth.[8]In a multicenter study, women who received a (Copper T 380A; N = 734) intrauterine device were compared to women who received a vaginal ring that released about 10 mg daily of progesterone (N = 802) beginning
. To study prospectively the evolution of body composition and bone mass in late-pubertal trans adolescents using the proandrogenic or antiandrogenic progestins lynestrenol (L) and cyproterone acetate (CA), respectively. Forty-four trans boys (Tanner B4/5) and 21 trans girls (Tanner G4/5) were treated with L or CA for 11.6 (4 to 40) and 10.6 (5 to 31) months, respectively. Anthropometry, grip strength
economic burden, being comparable to other chronic diseases like diabetes or rheumatoid arthritis. Therefore, the physicians dealing with this disease should take into account not only the efficacy of the treatment, but also the economic aspects and patients compliance. The present paper analyses the efficiency of progestins (lynestrenol and medrogestone) in endometriosis as a cost - effective
testosterone either intramuscularly (Nebido®) or transdermally (Testogel® or Testavan®). If necessary, the treatment might be supplemented by lynestrenol (Orgametril®).Furthermore, the treatment in both cohorts can, if necessary, be complemented by GnRH analogues, such as triptorelin acetate (Decapeptyl® or leuprorelin acetate every 3 months (Trenantone®).4. Methods and materials All measurements
factors for venous thromboembolic events. The current progestogen-only pills contain levonorgestrel, norethisterone, lynestrenol or ethynodiol diacetate have a multifaceted, mode of action . Ovulation inhibition is achieved in about half of the cycles and contributes only partly to the effectiveness of the method, with effects on the cervical mucus and the endometrium, thus providing additional
or progesterone; e.g. medroxyprogesteroneacetate (MPA), norethindrone (NET), norethindrone acetate (NETA), lynestrenol, dienogest, micronized progesterone(MP), levonorgestrel, norgestimat, gestode, desogestrel, drospirenone) for endometrial protection, or tissue seleciveestrogen complex (TSEC; CEE/bazedoxifene), as well as tibolone (selective tissue estrogenic activity regulator).Studies only reporting on local
: Class D (Strong evidence of risk to the human fetus) 1. Lynestrenol 2. Medroxyprogesterone 3. Methimazole 4. Propylthiouracil (preferred over Methimazole) 5. Tamoxifen 6. Tolbutamide (Orinase) VII. Category: Class X (Very high risk to the human fetus) 1. Clomiphene (Clomid) 2. Danazol 3. Diethylstilbesterol (DES) 4. Estrogens (all) 5. Iodide I-131 6. Leuprolide (Leupron) 7